RXRX Quote, Financials, Valuation and Earnings

Mirum Pharmaceuticals, Inc. has a net margin of -3135.32% compared to Recursion Pharmaceuticals, Inc.'s net margin of 2.18%. Recursion Pharmaceuticals, Inc.'s return on equity of -80.23% beat Mirum Pharmaceuticals, Inc.'s return on equity of -16.73%.

Recursion Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 104.68%. On the other hand Mirum Pharmaceuticals, Inc. has an analysts' consensus of $116.09 which suggests that it could grow by 10.4%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Mirum Pharmaceuticals, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Mirum Pharmaceuticals, Inc..

Recursion Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mirum Pharmaceuticals, Inc. has a beta of 0.492, suggesting its less volatile than the S&P 500 by 50.821%.

Recursion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mirum Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Mirum Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals, Inc. quarterly revenues are $5.2M, which are smaller than Mirum Pharmaceuticals, Inc. quarterly revenues of $133M. Recursion Pharmaceuticals, Inc.'s net income of -$162.3M is lower than Mirum Pharmaceuticals, Inc.'s net income of $2.9M. Notably, Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Mirum Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals, Inc. is 31.37x versus 11.35x for Mirum Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics, Inc. has a net margin of -3135.32% compared to Recursion Pharmaceuticals, Inc.'s net margin of -735.19%. Recursion Pharmaceuticals, Inc.'s return on equity of -80.23% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.

Recursion Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 104.68%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $23.86 which suggests that it could grow by 88.74%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Intellia Therapeutics, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Intellia Therapeutics, Inc..

Recursion Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.103, suggesting its more volatile than the S&P 500 by 110.271%.

Recursion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals, Inc. quarterly revenues are $5.2M, which are smaller than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Recursion Pharmaceuticals, Inc.'s net income of -$162.3M is lower than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals, Inc. is 31.37x versus 23.03x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tango Therapeutics, Inc. has a net margin of -3135.32% compared to Recursion Pharmaceuticals, Inc.'s net margin of 29.52%. Recursion Pharmaceuticals, Inc.'s return on equity of -80.23% beat Tango Therapeutics, Inc.'s return on equity of -56.44%.

Recursion Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 104.68%. On the other hand Tango Therapeutics, Inc. has an analysts' consensus of $15.25 which suggests that it could grow by 25%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Tango Therapeutics, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Tango Therapeutics, Inc..

Recursion Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tango Therapeutics, Inc. has a beta of 1.750, suggesting its more volatile than the S&P 500 by 75.038%.

Recursion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tango Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Tango Therapeutics, Inc. pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals, Inc. quarterly revenues are $5.2M, which are smaller than Tango Therapeutics, Inc. quarterly revenues of $53.8M. Recursion Pharmaceuticals, Inc.'s net income of -$162.3M is lower than Tango Therapeutics, Inc.'s net income of $15.9M. Notably, Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Tango Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals, Inc. is 31.37x versus 20.20x for Tango Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XOMA Royalty Corp. has a net margin of -3135.32% compared to Recursion Pharmaceuticals, Inc.'s net margin of 52.48%. Recursion Pharmaceuticals, Inc.'s return on equity of -80.23% beat XOMA Royalty Corp.'s return on equity of 17.31%.

Recursion Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 104.68%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $64.50 which suggests that it could grow by 149.9%. Given that XOMA Royalty Corp. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe XOMA Royalty Corp. is more attractive than Recursion Pharmaceuticals, Inc..

Recursion Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.855, suggesting its less volatile than the S&P 500 by 14.461%.

Recursion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Recursion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Recursion Pharmaceuticals, Inc. quarterly revenues are $5.2M, which are smaller than XOMA Royalty Corp. quarterly revenues of $9.4M. Recursion Pharmaceuticals, Inc.'s net income of -$162.3M is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 34.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals, Inc. is 31.37x versus 8.98x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.